The donated non-factor replacement therapy will be used by the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with hemophilia A in countries where there is little or no access to treatment. The partnership between Roche and the WFH began in 2019 and was a milestone because it marked the first time that patients in developing countries had received access to non-factor replacement therapy. The donated treatment has since benefited more than 940 people across 30 countries.
“Our renewed commitment will allow us to continue to help people with haemophilia A most in need,” said Bill Anderson, CEO Roche Pharmaceuticals. “We are proud to be recognised by the WFH as a Visionary Contributor of the Program and are delighted to announce that our commitment to the WFH Humanitarian Aid Program has been extended until 2028.”
Cesar Garrido, WFH President, also praised Roche for extending their commitment to the global bleeding disorders community. “Last year was a record year for the WFH Humanitarian Aid Program, which continues to make life-changing treatment accessible for those who need it most,” he said. “With Roche’s continued support, we will be able to continue the important work that the Humanitarian Aid Program does, giving people with bleeding disorders the hope of leading a normal life through prophylactic treatment.”
From the WFH, Cesar Garrido, President; Eric Stolte, WFH USA President, Alain Baumann, CEO; Assad E. Haffar, MD, Medical & Humanitarian Aid Director; were present to officially sign the agreement. From the Roche team, Iqbal Mufti, Martynas Aizenas, Lutz Knabe, Tuende Czirok, Dan Freeman, Katya Moreno and Kentaro Kishi (Chugai) were present.
À propos du Programme d’aide humanitaire de la fmh
Le Programme d’aide humanitaire de la FMH améliore l’accès aux soins et aux traitements en fournissant un soutien essentiel aux personnes atteintes de troubles héréditaires de la coagulation dans les pays en développement. En apportant aux patients un flux plus régulier et plus prévisible de dons humanitaires, le Programme d’aide humanitaire de la FMH leur permet un accès constant et fiable aux traitements et aux soins. Rien de tout cela ne serait possible sans le généreux soutien de Sanofi Genzyme et Sobi, nos Donateurs visionnaires fondateurs ; de Roche et Bayer, nos Donateurs visionnaires ; de Grifols, notre Donateur encadrant, et de nos Donateurs contributeurs CSL Behring et Takeda. Pour plus d’informations sur le Programme d’aide humanitaire de la FMH, consultez le site www.treatmentforall.org.